-
Mashup Score: 33Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients - 1 month(s) ago
Low-dose emicizumab can potentially offer a cost-effective treatment option in persons with hemophilia A, especially in developing countries.
Source: www.jthjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Guy Young, MD: More Advancement for Subcutaneous Hemophilia Treatments - 10 month(s) ago
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician…
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Unlocking new possibilities in hemophilia treatment: Dr. Guy Young discusses Roctavian, Hemlibra and beyond. #Genetherapy #Hemlibra @GuyYoungMD https://t.co/AVszrVdZjY
-
-
Mashup Score: 0Agent exhibits ‘significant evidence of efficacy’ for infants with severe hemophilia A - 1 year(s) ago
NEW ORLEANS — Emicizumab-kxwh prophylaxis appeared effective and safe for infants with severe hemophilia A without factor VIII inhibitors, according to study results presented at ASH Annual Meeting and Exposition.Analyses showed “significant evidence of efficacy” with emicizumab-kxwh (Hemlibra, Genentech) for this patient population, researcher Steven W. Pipe, MD, professor of
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Agent exhibits ‘significant evidence of efficacy’ for infants with severe hemophilia A. https://t.co/cysvlxvIu0 #ASH22 @ASH_hematology #HemOnc #OncAlert #MedEd @UMich #Hemlibra @genentech @umichmedicine @UMRogelCancer
-
-
Mashup Score: 4Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies - 1 year(s) ago
Key Points. This is the largest summary to date of the management of people with hemophilia A on emicizumab prophylaxis undergoing surgery.Major and minor surge
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
The largest series of surgery in persons with #hemophilia on #emicizumab (#Hemlibra) has been published in @BloodAdvances. 215 minor and 18 major surgeries. However only 29 dental extractions and 5 arthroplasties were included. https://t.co/HyhyALgcPO 1/2 https://t.co/hfm6ZAMpBw
-
-
Mashup Score: 4Chugai Pharmaceutical : Obtains Regulatory Approval for Hemlibra for Additional Indication of Acquired Hemophilia A | MarketScreener - 2 year(s) ago
Chugai Obtains Regulatory Approval for Hemlibra for Additional Indication of Acquired Hemophilia A The approval is based on the results of a Japanese… | June 20, 2022
Source: www.marketscreener.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Important. Emicizumab (#Hemlibra) has been approved for use in acquired #hemophilia A in Japan. The way this disease is treated is about to be transformed. Note rapid loading: 6mg/kg day 1, 3mg/kg day 2, then 1.5mg/kg weekly. https://t.co/IRs4fGNkJC 1/2
-
-
Mashup Score: 0Calibra™ Demo - 2 year(s) ago
Calibra™ is the newly developed tool that minimizes waste of Emicizumab by calculating the most efficient combinations of full vials. It then computes the r…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
It is great to see the Calibra app that works with WAPPS to optimise emicizumab (#Hemlibra) treatment in #hemophilia A. It will tell you the best way to give this drug to minimise the number of injections per year and also minimise wastage. https://t.co/jj5aPY227P 2/2
-
-
Mashup Score: 0Chugai files for new indication for Hemlibra in hemophilia A - 2 year(s) ago
Chugai files for new indication for Hemlibra in hemophilia A
Source: www.thepharmaletter.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Chugai, the company that developed emicizumab (#Hemlibra) has applied in Japan for approval for its use in patients with acquired #hemophilia A. https://t.co/viB5pHMvYb
-
-
Mashup Score: 2Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A - PubMed - 3 year(s) ago
The appearance of ADAs with emicizumab-neutralizing activity and potential to accelerate emicizumab clearance decreased the efficacy of emicizumab.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Paper in press in JTH describes another patient with completely neutralising antibodies to emicizumab. The number of published cases is now 4. Rate remains less than 1 in 1000. https://t.co/Xz0LwbRTIu #hemophilia #Hemlibra #emicizumab #haemophilia https://t.co/iY7rfphxXU
-
-
Mashup Score: 12
Abstract Emicizumab, a bispecific antibody mimicking the action of factor VIII (FVIII), is currently the first and only approved and increasingly accessible disruptive treatment option for hemophilia A, a disease so far mainly treated with frequent intravenous infusions of FVIII concentrates or bypassing agents in case of inhibitor development. Other disruptive treatments are…
Source: onlinelibrary.wiley.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Our paper on the disruptive impact of emicizumab in #hemophilia care has been published online early by the @RPTHjournal today. Have a look and let us know if you disagree. https://t.co/VNdRFkcpV7 #haemophilia #Hemlibra
-
-
Mashup Score: 0Baxalta Wins New Try at Hemophilia Drug Patent Infringement Suit - 4 year(s) ago
Genentech Inc. will have to face revived claims that its hemophilia treatment infringes Baxalta Inc.’s patent for an antibody that increases blood-clotting activity.
Source: news.bloomberglaw.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Just when we all thought that the legal battle between Baxalta/Takeda and Genentech/Takeda regarding #emicizumab (#Hemlibra) was over, it is about to restart. https://t.co/yYUnIYRGAV
-
Small study but impressive, important results. Half dose emicizumab (#Hemlibra) produced excellent results and it was cheaper than FVIII prophylaxis. Paper in @JTHjournal but PDF behind paywall. https://t.co/AIfELc5zge https://t.co/mlBIw0aMI3